SNGX on Nasdaq

SOLIGENIX, INC.

American pharmaceutical preparations company based in Princeton.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with BullFrog AI Holdings, Inc., Nkarta Therapeutics (United States) or Serina Therapeutics, Inc., or pick any stock.

  • TickerSNGX on Nasdaq
  • IndustryPharmaceutical Preparations
  • HeadquartersPrinceton, United States
  • Incorporated inDE2
  • Business address29 Emmons Drive, Suite B-10, Princeton, Nj 085402
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

-7907.7%Operating margin3
-6925.1%Net margin3
-85.8%Revenue growth, 20243
-200.7%Return on equity3
0.00×Debt to equity4

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Cost of revenue2¢$119.4K
  • Research and development91¢$5.2M
  • Income tax7¢$409.1K

Out of $119.4K in revenue.3 The company lost money this year.

Financial statements

Revenue567843$119.4K in 2024−97% since 2019
0$2.0M$4.0M$6.0M2019: $4.6M$4.6M20192020: $2.4M$2.4M2020−49%2021: $824.3K$824.3K2021−65%2022: $948.9K$948.9K2022+15%2023: $839.4K$839.4K2023−12%2024: $119.4K$119.4K2024−86%
Gross profit56784$97.3K in 2023−91% since 2019
0$500.0K$1.0M$1.5M2019: $1.1M$1.1M20192020: $538.5K$538.5K2020−49%2021: $95.6K$95.6K2021−82%2022: $398.1K$398.1K2022+316%2023: $97.3K$97.3K2023−76%
Operating income567843-$9.4M in 2024−10% since 2019
-$20.0M-$15.0M-$10.0M-$5.0M02019: -$10.5M-$10.5M20192020: -$18.6M-$18.6M2020+76%2021: -$13.1M-$13.1M2021−30%2022: -$14.2M-$14.2M2022+9%2023: -$7.7M-$7.7M2023−46%2024: -$9.4M-$9.4M2024+23%
Net income567843-$8.3M in 2024−12% since 2019
-$20.0M-$15.0M-$10.0M-$5.0M02019: -$9.4M-$9.4M20192020: -$17.7M-$17.7M2020+89%2021: -$12.6M-$12.6M2021−29%2022: -$13.8M-$13.8M2022+10%2023: -$6.1M-$6.1M2023−55%2024: -$8.3M-$8.3M2024+35%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2025-12-312024-12-31
Total revenues$119.4K
Cost of revenues-$119.4K
Research and development$7.5M$5.2M
General and administrative$4.4M$4.2M
Total operating expenses$11.8M$9.4M
Loss from operations-$11.8M-$9.4M
Foreign currency transaction (loss) gain-$11.8K$1.6K
Interest income, net$270.2K$214.0K
Research and development incentives-$25.5K
CARES Act employee retention credit$312.8K
Other income$125$43
Change in fair value of convertible debt$260.9K
Total other income$258.5K$763.8K
Net loss before income taxes-$11.6M-$8.7M
Income tax benefit$506.6K$409.1K
Net loss applicable to common stockholders-$11.1M-$8.3M
Basic net loss per share (in Dollars per share)-$2.14-$4.98
Diluted net loss per share (in Dollars per share)-$2.14-$4.98
Basic weighted average common shares outstanding (in Shares)5.2M shares1.7M shares
Diluted weighted average common shares outstanding (in Shares)5.2M shares1.7M shares

Compare SOLIGENIX, INC. with another company

Leadership

Who has led SOLIGENIX, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Michael T. Sember2006
  2. Christopher Schaber2006–now

Chair

  1. Christopher Schaber2010–now

President

  1. Christopher Schaber2006–now

Chief financial officer

  1. Evan Myrianthopoulos2006–2011
  2. Joseph Michael Warusz2013–2016
  3. Karen R. Krumeich2016–2018
  4. Jonathan L. Guarino2019–now
2010201520202025
Board members and other officers (24)

Former names

  • DOR BIOPHARMA INCApr 1, 2002 to Sep 29, 20092
  • ENDOREX CORPSep 16, 1996 to Oct 24, 20012
  • IMMUNOTHERAPEUTICS INCAug 8, 1995 to Apr 30, 19962

Timeline

  1. Sep 1, 2006New chief executive Christopher Schaber becomes CEO12
  2. Apr 10, 2006New chief executive Michael T. Sember becomes CEO11

Filings

257 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 55 major events, 59 insider forms, 4 large holders, 119 other. The latest 20:

  1. Oct 13, 20264 EDGAR
  2. Oct 13, 20264 EDGAR
  3. Oct 13, 20264 EDGAR
  4. Oct 13, 20264 EDGAR
  5. Oct 13, 20264 EDGAR
  6. Oct 13, 20264 EDGAR
  7. Oct 13, 20264 EDGAR
  8. Sep 21, 20268-K EDGAR
  9. Sep 18, 20264 EDGAR
  10. Sep 18, 20264 EDGAR
  11. Sep 18, 20264 EDGAR
  12. Sep 18, 20264 EDGAR
  13. Aug 7, 2026424B3 EDGAR
  14. Aug 7, 2026424B3 EDGAR
  15. Aug 7, 2026424B3 EDGAR
  16. Aug 7, 2026424B3 EDGAR
  17. Aug 7, 202610-Q EDGAR
  18. Aug 3, 2026ARS EDGAR
  19. Aug 3, 2026DEFA14A EDGAR
  20. Aug 3, 2026DEF 14A EDGAR

The 257 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 4 such filings since October 2021:

  1. Jun 25, 2026SCHEDULE 13G
  2. Feb 17, 2026SCHEDULE 13G/A
  3. Nov 14, 2025SCHEDULE 13G
  4. Oct 1, 2025SCHEDULE 13G

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Citadel Advisors LLC209,507$83.0K0.0%New
Jane Street Group, LLC207,492$82.2K0.0%New
XTX Topco Ltd157,119$62.2K0.0%+136,320
Geode Capital Management, LLC120,267$47.6K0.0%No change
Vanguard Capital Management LLC81,005$32.1K0.0%+22,605
Vanguard Fiduciary Trust Co53,914$21.4K0.0%No change
Northern Trust Corp38,046$15.1K0.0%New
Morgan Stanley3,592$1.4K0.0%No change
Jones Financial Companies Lllp1,236$5070.0%+1,136
Jpmorgan Chase & Co245$980.0%−60
Plante Moran Financial Advisors, LLC209$830.0%No change
Virtu Financial LLC60,903$240.0%New
Albion Financial Group /ut1$10.0%No change
SBI Securities Co., Ltd.2$10.0%−400
Royal Bank Of Canada5$00.0%New
Osaic Holdings, Inc.1$00.0%−1
Caitong International Asset Management Co., Ltd1$00.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38